Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide switch study for poor quality of life despite magnesium oxide in adult chronic constipation
jRCTs031200048Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of linaclotide in chronic constipation and irritable bowel syndrome (IBS), sponsored by Astellas Pharma. Primary endpoint: Change in JPAC-QOL score from baseline at 12 weeks. Started Jul 2020; status: completed.
02
Drugs
linaclotide
03
Conditions
chronic constipationirritable bowel syndrome (IBS)
Beyond the preview
Go deeper on jRCTs031200048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200048.